The present disclosure is directed to compounds and methods for the treatment of disorders associated with fluid retention or salt overload, such as heart failure (in particular, congestive heart failure), chronic kidney disease, end-stage renal disease, liver disease, and peroxisome proliferator-activated receptor (PPAR) gamma agonist-induced fluid retention. The present disclosure is also directed to compounds and methods for the treatment of hypertension. The present disclosure is also directed to compounds and methods for the treatment of gastrointestinal tract disorders, including the treatment or reduction of pain associated with gastrointestinal tract disorders. The methods generally comprise administering to a mammal in need thereof a pharmaceutically effective amount of a compound, or a pharmaceutical composition comprising such a compound, that is designed to be substantially active in the gastrointestinal (GI) tract to inhibit NHE-mediated antiport of sodium ions and hydrogen ions therein. More particularly, the method comprises administering to a mammal in need thereof a pharmaceutically effective amount of a compound, or a pharmaceutical composition comprising such a compound, that inhibits NHE-3, -2 and/or -8 mediated antiport of sodium and/or hydrogen ions in the GI tract and is designed to be substantially impermeable to the layer of epithelial cells, or more specifically the epithelium of the GI tract. As a result of the compound being substantially impermeable, it is not absorbed and is thus essentially systemically non-bioavailable, so as to limit the exposure of other internal organs (e.g., liver, heart, brain, etc.) thereto. The present disclosure is still further directed to a method wherein a mammal is administered such a compound with a fluid-absorbing polymer, such that the combination acts as described above and further provides the ability to sequester fluid and/or salt present in the GI tract.

Compounds, methods of use, and processes for making inhibitors of Complement Factor B are provided.

An electronic switching device, in particular tunnel junctions, containing an organic molecular layer for use in memory, sensors, field-effect transistors or Josephson junctions. More particularly, related to the field of random access non-volatile memristive memories (RRAM). Another aspect is a compound of formula I

##STR00001##

for use in a molecular layer. Also, the use of the molecular layer and processes for the production and operation of an electronic switching element and components based thereon.

The invention provides a composition and method for improving the selectivity of nitride etching versus oxide etching and can be used with conventional phosphoric acid wet etch compositions. The invention describes additives that serve to inhibit silicon, oxides, and related compounds regrowth (i.e., redeposition) on the silicon oxide surface. In certain embodiments, the invention provides certain amino-substituted aryl compounds which are bound to a tri-alkoxy silane.

Non-halogenated melamine compounds for use as flame retardants are characterized by having a TGA.sub.25 value of at least 200 degrees Centigrade, a TGA.sub.50 value of at least 300 degrees Centigrade, or a TGA.sub.75 value of at least 500 degrees Centigrade, as measured on a thermogravimetric analysis (TGA) curve produced at a heating rate of 10 degrees Centigrade per minute and at a 60 mL/min oxygen or nitrogen flow, said compounds being small molecules, linear or branched polymers, or salts thereof.

A near-infrared absorbing composition includes: an organic dye; and a metal compound. The organic dye includes: at least one of a squarylium dye (A) or a cyanine dye (B) each having an absorption maximum in a range of 680 to 740 nm; and a cyanine dye (C) having an absorption maximum at 760 nm or higher. The metal compound includes at least a phosphonic acid and a copper ion, or a copper phosphonate complex formed from a phosphonic acid and a copper ion.

The invention provides a composition and method for improving the selectivity of nitride etching versus oxide etching and can be used with conventional phosphoric acid wet etch compositions. The invention describes additives that serve to inhibit silicon, oxides, and related compounds regrowth (i.e., redeposition) on the silicon oxide surface. In certain embodiments, the invention provides certain amino-substituted aryl compounds which are bound to a tri-alkoxy silane.

A light-absorbing composition includes: a light absorber formed by a phosphonic acid represented by the following formula (a) and copper ion, the light absorber being dispersed in the light-absorbing composition; a phosphoric acid ester allowing the light absorber to be dispersed; and a curable resin. When the light-absorbing composition is applied and cured on one principal surface of a transparent dielectric substrate to form a laminate consisting of a light-absorbing layer being a cured product of the light-absorbing composition and the transparent dielectric substrate, the laminate satisfies predetermined requirements. ##STR00001##

The present invention has an object to provide a positive electrode active material for a magnesium battery; and a magnesium battery which has a high operating voltage with respect to magnesium and can be repeatedly charged and discharged at a high capacity retention rate, using the positive electrode active material.

The present invention relates to a positive electrode active material for a magnesium battery, containing a compound represented by the general formula (1), a positive electrode material composition for a magnesium battery, a positive electrode for a magnesium battery, and a magnesium battery:

Ag.sub.pSO.sub.4  (1) [in the formula (1), p satisfies 0<p≤2].

The present disclosure provides compositions and methods for using fixed biological samples in partition-based assays. In at least one embodiment, the disclosure provides a composition comprising a fixed biological sample and an un-fixing agent contained in a partition, such as a discrete droplet. In some embodiments, the disclosure provides un-fixing agent compounds capable of catalytically cleaving crosslinks in fixed biological samples, particularly crosslinked nucleic acids, such as RNA.